| Market revenue in 2025 | USD 420.5 million |
| Market revenue in 2033 | USD 774.5 million |
| Growth rate | 8% (CAGR from 2026 to 2033) |
| Largest segment | Drug discovery programs |
| Fastest growing segment | Cell- & organ-based screening |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Drug discovery programs, Chemical biology programs, Biochemical screening, Cell- & organ-based screening |
| Key market players worldwide | Agilent Technologies Inc, Danaher Corp, Thermo Fisher Scientific Inc, PerkinElmer, Bio-Rad Laboratories Inc, Aurora Biomed, Tecan Group AG, Promega Corporation, Charles River Laboratories International Inc, Creative-Biolabs |
Publish Date: Apr 01, 2026
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| PerkinElmer | View profile | 10001+ | Waltham, Massachusetts, United States, North America | www.perkinelmer.com |
| Tecan Group AG | View profile | 3,591 | Seestrasse 103, Mannedorf, Switzerland, 8708 | www.tecan.com |
| Creative-Biolabs | View profile | 51-100 | Shirley, New York, United States, North America | www.creative-biolabs.com |
| Promega Corporation | View profile | - | - | - |
| Aurora Biomed | View profile | 11-50 | Vancouver, British Columbia, Canada, North America | www.aurorabiomed.com |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to High Throughput Screening Market Outlook will help companies and investors design strategic landscapes.
Drug Discovery Programs was the largest segment with a revenue share of 61.09% in 2025.
Horizon Databook has segmented the Spain high throughput screening market based on drug discovery programs, chemical biology programs, biochemical screening, cell- & organ-based screening covering the revenue growth of each sub-segment from 2021 to 2033.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain High Throughput Screening Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Spain High Throughput Screening Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
